Vera Therapeutics, Inc. (VERA)Healthcare | Biotechnology | Brisbane, United States | NasdaqGM
34.19 USD
-0.41
(-1.185%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 33.91 -0.28 (-0.280%) ⇩ (Aug. 28, 2026, 7:58 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 5:34 a.m. EDT
The investment case here is fraught with contradictions between the company's operational milestones and its financial reality. On the bright side, the recent FDA approval for TRUTAKNA is a massive catalyst, and the stock has already rallied significantly, yet it remains well below its 52-week high, leaving room for further upside if the product gains traction. However, the fundamental picture is dire: the company is burning through cash with negative free cash flow and negative returns on equity, relying entirely on capital raises to stay alive. The balance sheet is fragile, and the stock trades at a premium to book value despite these losses. Technically, the stock is struggling to break out of a downtrend, trading below both its 50-day and 200-day moving averages, which suggests institutional sellers are still in control. While the analyst consensus is a 'strong buy' with a lofty target price, this appears to be pricing in a perfect execution of the new drug without accounting for the high probability of dilution from the recent $300 million offering. The options market reflects this caution, with heavy put writing at lower levels capping the downside but also preventing a runaway rally. This is a speculative play on a binary event (drug adoption) rather than a sound long-term investment, making it unsuitable for most portfolios. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.143257 |
| AutoTheta | 0.159103 |
| AutoARIMA | 0.159107 |
| AutoETS | 0.159107 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 41% |
| H-stat | 0.51 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.158 |
| Excess Kurtosis | -1.40 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 18.86 |
| Market Cap | 2,463,845,376 |
| Forward P/E | -7.75 |
| Beta | 0.95 |
| Website | https://veratx.com |
As of Aug. 22, 2026, 5:34 a.m. EDT: Speculators are positioning for a range-bound recovery rather than a breakout. Call open interest is heavily concentrated at the $35 strike across multiple expirations, acting as a significant resistance wall. Conversely, put open interest is substantial at lower strikes ($25-$30), particularly for longer-dated contracts, suggesting a floor is being established. The imbalance in volume versus open interest at the $40 strike indicates fresh selling pressure or a lack of aggressive buying there, while the ATM anchor shows mixed sentiment with neither side dominating the immediate term.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.5302963 |
| Address1 | 2,000 Sierra Point Parkway |
| Address2 | Suite 1200 |
| All Time High | 56.05 |
| All Time Low | 5.2 |
| Ask | 38.91 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 2,382,770 |
| Average Daily Volume3 Month | 2,094,187 |
| Average Volume | 2,094,187 |
| Average Volume10Days | 2,382,770 |
| Beta | 0.954 |
| Bid | 22.14 |
| Bid Size | 1 |
| Board Risk | 6 |
| Book Value | 5.667 |
| City | Brisbane |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 34.19 |
| Current Ratio | 10.916 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 34.42 |
| Day Low | 33.34 |
| Debt To Equity | 18.86 |
| Display Name | Vera Therapeutics |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -415,224,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.917 |
| Enterprise Value | 2,041,589,376 |
| Eps Current Year | -6.32203 |
| Eps Forward | -4.4139 |
| Eps Trailing Twelve Months | -5.8 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 36.2395 |
| Fifty Day Average Change | -2.0494995 |
| Fifty Day Average Change Percent | -0.056554303 |
| Fifty Two Week Change Percent | 53.029633 |
| Fifty Two Week High | 56.05 |
| Fifty Two Week High Change | -21.86 |
| Fifty Two Week High Change Percent | -0.39000893 |
| Fifty Two Week Low | 21.645 |
| Fifty Two Week Low Change | 12.544998 |
| Fifty Two Week Low Change Percent | 0.5795795 |
| Fifty Two Week Range | 21.645 - 56.05 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,620,999,000,000 |
| Float Shares | 52,394,368 |
| Forward Eps | -4.4139 |
| Forward P E | -7.745984 |
| Free Cashflow | -212,947,376 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 361 |
| Fullday Change | -0.41 |
| Fullday Change Percent | -1.18497 |
| Fullday Price | 33.91 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00954 |
| Held Percent Institutions | 1.1796 |
| Implied Shares Outstanding | 72,063,335 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-05-14 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune kidney diseases. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections that has completed phase 2 clinical trial; and VT-109, a novel BAFF/APRIL dual-inhibitor B cell maturation antigen (BCMA) molecule to treat B cell mediated autoimmune diseases. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California. |
| Long Name | Vera Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 2,463,845,376 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_683328925 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -401,895,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 2,493,031,074 |
| Number Of Analyst Opinions | 14 |
| Open | 34.4 |
| Operating Cashflow | -338,652,992 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 650 770 0077 |
| Post Market Change | -0.27999878 |
| Post Market Change Percent | -0.8189494 |
| Post Market Price | 33.91 |
| Post Market Time | 1,787,961,531 |
| Previous Close | 34.6 |
| Price Eps Current Year | -5.408073 |
| Price Hint | 2 |
| Price To Book | 6.0331745 |
| Profit Margins | 0.0 |
| Quick Ratio | 10.411 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.21429 |
| Region | US |
| Regular Market Change | -0.41 |
| Regular Market Change Percent | -1.18497 |
| Regular Market Day High | 34.42 |
| Regular Market Day Low | 33.34 |
| Regular Market Day Range | 33.34 - 34.42 |
| Regular Market Open | 34.4 |
| Regular Market Previous Close | 34.6 |
| Regular Market Price | 34.19 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 1,256,413 |
| Return On Assets | -0.46756 |
| Return On Equity | -0.91753 |
| Sand P52 Week Change | 0.20504117 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 72,063,335 |
| Shares Percent Shares Out | 0.2333 |
| Shares Short | 16,814,429 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 15,081,995 |
| Short Name | Vera Therapeutics, Inc. |
| Short Percent Of Float | 0.2656 |
| Short Ratio | 8.21 |
| Source Interval | 15 |
| State | CA |
| Symbol | VERA |
| Target High Price | 100.0 |
| Target Low Price | 34.0 |
| Target Mean Price | 77.14286 |
| Target Median Price | 79.0 |
| Total Cash | 499,160,992 |
| Total Cash Per Share | 6.927 |
| Total Debt | 76,905,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.8 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 39.27075 |
| Two Hundred Day Average Change | -5.0807495 |
| Two Hundred Day Average Change Percent | -0.12937745 |
| Type Disp | Equity |
| Volume | 1,256,413 |
| Website | https://veratx.com |
| Zip | 94,005 |